Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 303

1.

Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine Workshop highlights and next steps.

Kirch R, Reaman G, Feudtner C, Wiener L, Schwartz LA, Sung L, Wolfe J.

CA Cancer J Clin. 2016 May 4. doi: 10.3322/caac.21347. [Epub ahead of print] Review.

2.

An FDA oncology view of juvenile animal studies in support of initial pediatric trials for anticancer drugs.

Leighton JK, Saber H, Reaman G, Pazdur R.

Regul Toxicol Pharmacol. 2016 Aug;79:142-3. doi: 10.1016/j.yrtph.2016.03.001. Epub 2016 Mar 4. No abstract available.

PMID:
26952647
3.

Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.

Meany HJ, Seibel NL, Krailo M, Villaluna D, Chen Z, Gaynon P, Neglia JP, Park JR, Hutchinson R, Sato JK, Wells RJ, Woods WG, Reaman G.

J Immunother. 2015 Sep;38(7):299-305. doi: 10.1097/CJI.0000000000000088.

PMID:
26261894
4.

Regulatory perspective on minimal residual disease flow cytometry testing in multiple myeloma.

Gormley NJ, Turley DM, Dickey JS, Farrell AT, Reaman GH, Stafford E, Carrington L, Marti GE.

Cytometry B Clin Cytom. 2016 Jan;90(1):73-80. doi: 10.1002/cyto.b.21268. Epub 2015 Jul 25.

PMID:
26108351
5.

Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports.

Cope JU, Reaman GH, Tonning JM.

Sarcoma. 2015;2015:948159. doi: 10.1155/2015/948159. Epub 2015 May 7. Review.

6.

CD22ΔE12 as a molecular target for corrective repair using RNA trans-splicing: anti-leukemic activity of a rationally designed RNA trans-splicing molecule.

Uckun FM, Qazi S, Ma H, Reaman GH, Mitchell LG.

Integr Biol (Camb). 2015 Feb;7(2):237-49. doi: 10.1039/c4ib00221k.

7.

Remaining challenges in childhood cancer and newer targeted therapeutics.

Smith MA, Reaman GH.

Pediatr Clin North Am. 2015 Feb;62(1):301-12. doi: 10.1016/j.pcl.2014.09.018. Epub 2014 Oct 18. Review.

8.

Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3).

Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, Camitta BM.

Pediatr Blood Cancer. 2015 Mar;62(3):419-26. doi: 10.1002/pbc.25322. Epub 2014 Nov 14.

PMID:
25399948
9.

Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.

Angiolillo AL, Schore RJ, Devidas M, Borowitz MJ, Carroll AJ, Gastier-Foster JM, Heerema NA, Keilani T, Lane AR, Loh ML, Reaman GH, Adamson PC, Wood B, Wood C, Zheng HW, Raetz EA, Winick NJ, Carroll WL, Hunger SP.

J Clin Oncol. 2014 Dec 1;32(34):3874-82. doi: 10.1200/JCO.2014.55.5763. Epub 2014 Oct 27.

10.

Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group.

Thompson P, Wheeler HE, Delaney SM, Lorier R, Broeckel U, Devidas M, Reaman GH, Scorsone K, Sung L, Dolan ME, Berg SL.

Cancer Chemother Pharmacol. 2014 Oct;74(4):831-8. doi: 10.1007/s00280-014-2535-4. Epub 2014 Aug 14.

11.

International patterns of childhood chronic myeloid leukemia: comparisons between the United States and resource-restricted nations.

Sadak KT, Fultz K, Mendizabal A, Reaman G, Garcia-Gonzalez P, Levine PH.

Pediatr Blood Cancer. 2014 Oct;61(10):1774-8. doi: 10.1002/pbc.25120. Epub 2014 Jun 29.

PMID:
24976310
12.

The Children's Oncology Group Childhood Cancer Research Network (CCRN): case catchment in the United States.

Musselman JR, Spector LG, Krailo MD, Reaman GH, Linabery AM, Poynter JN, Stork SK, Adamson PC, Ross JA.

Cancer. 2014 Oct 1;120(19):3007-15. doi: 10.1002/cncr.28813. Epub 2014 May 29.

13.

Declining childhood and adolescent cancer mortality.

Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL.

Cancer. 2014 Aug 15;120(16):2497-506. doi: 10.1002/cncr.28748. Epub 2014 May 22.

14.

DrugPath: a database for academic investigators to match oncology molecular targets with drugs in development.

Shah ED, Fisch BM, Arceci RJ, Buckley JD, Reaman GH, Sorensen PH, Triche TJ, Reynolds CP.

Cancer Chemother Pharmacol. 2014 May;73(5):1089-93. doi: 10.1007/s00280-014-2433-9. Epub 2014 Mar 25.

PMID:
24663501
15.

Childhood acute lymphoblastic leukemia in the Middle East and neighboring countries: a prospective multi-institutional international collaborative study (CALLME1) by the Middle East Childhood Cancer Alliance (MECCA).

Al-Mulla NA, Chandra P, Khattab M, Madanat F, Vossough P, Torfa E, Al-Lamki Z, Zain G, Muwakkit S, Mahmoud S, Al-Jassmi A, Tuncer M, Al-Mukharraq H, Barsaoui S, Arceci RJ, Howard SC, Kulozik AE, Ravindranath Y, Reaman GH, Farranoush M, AlNasser AA.

Pediatr Blood Cancer. 2014 Aug;61(8):1403-10. doi: 10.1002/pbc.25031. Epub 2014 Mar 20.

PMID:
24648275
16.

Pediatric oncology drug shortages: a multifaceted problem.

Murphy D, Reaman G, Jensen CV.

Pediatrics. 2014 Mar;133(3):e728-9. doi: 10.1542/peds.2013-4018. Epub 2014 Feb 2. No abstract available.

17.

Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Children's Oncology Group.

Salzer WL, Asselin B, Supko JG, Devidas M, Kaiser NA, Plourde P, Winick NJ, Reaman GH, Raetz E, Carroll WL, Hunger SP.

Blood. 2013 Jul 25;122(4):507-14. doi: 10.1182/blood-2013-01-480822. Epub 2013 Jun 5.

18.

Patient-perceived facilitators in the transition of care for young adult survivors of childhood cancer.

Sadak KT, Dinofia A, Reaman G.

Pediatr Blood Cancer. 2013 Aug;60(8):1365-8. doi: 10.1002/pbc.24494. Epub 2013 Feb 25. Review.

PMID:
23441065
19.

Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries.

Pritchard-Jones K, Pieters R, Reaman GH, Hjorth L, Downie P, Calaminus G, Naafs-Wilstra MC, Steliarova-Foucher E.

Lancet Oncol. 2013 Mar;14(3):e95-e103. doi: 10.1016/S1470-2045(13)70010-X. Epub 2013 Feb 20.

PMID:
23434338
20.

Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia.

Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, Cao K, Cory L, Moore JS, Bantly AD, Yu QC, Chen IM, Atlas SR, Willman CL, Kundu M, Carroll AJ, Heerema NA, Devidas M, Hilden JM, Dreyer ZE, Hunger SP, Reaman GH, Felix CA.

Blood. 2013 Apr 4;121(14):2689-703. doi: 10.1182/blood-2012-04-425033. Epub 2013 Feb 7.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk